1. 235 IKZF1 and IKZF3 inhibition impairs B cell differentiation and modulates gene expression in systemic lupus erythematosus. (April 2019) Authors: Manou-Stathopoulou, Sotiria; Rivellese, Felice; Mauro, Daniele; Goldmann, Katriona; Pyne, Debasish; Schafer, Peter; Bombardieri, Michele; Pitzalis, Costantino; Lewis, Myles Journal: Lupus science & medicine Issue: Volume 6(2019)supplement 1 Page Start: A174 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0179 THE TRANSCRIPTION FACTORS IKZF1 AND IKZF3 CONTROL B CELL ACTIVATION AND DIFFERENTIATION IN SYSTEMIC LUPUS ERYTHEMATOSUS. (June 2019) Authors: Manou-Stathopoulou, Sotiria; Rivellese, Felice; Mauro, Daniele; Goldmann, Katriona; Pyne, Debasish; Schafer, Peter; Bombardieri, Michele; Pitzalis, Costantino; Lewis, Myles Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 1548 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Issue 3 (December 2019) Authors: Strober, Bruce; Alikhan, Ali; Lockshin, Benjamin; Shi, Rebecca; Cirulli, Joshua; Schafer, Peter Journal: Journal of dermatological science Issue: Volume 96:Issue 3(2019) Page Start: 126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Issue 1 (December 2015) Authors: Perez-Aso, Miguel; Montesinos, M.; Mediero, Aránzazu; Wilder, Tuere; Schafer, Peter; Cronstein, Bruce Journal: Arthritis research & therapy Issue: Volume 17:Issue 1(2015) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CT-07 A phase 2, randomised, placebo-controlled, double-blind, ascending dose study to evaluate efficacy, safety, and tolerability, pharmacokinetics, pharmacodynamics and pharmacogenetics of CC-220 in subjects with systemic lupus erythematosus. (31st August 2016) Authors: Werth, Victoria; Hough, Douglas; Korish, Shimon; Weiswasser, Michael; Schafer, Peter; Delev, Nikolay; Choi, Suktai Journal: Lupus science & medicine Issue: Volume 3(2016)Supplement 1 Page Start: A41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Effects of targeting the transcription factors Ikaros and Aiolos on B cell activation and differentiation in systemic lupus erythematosus. Issue 1 (16th March 2021) Authors: Rivellese, Felice; Manou-Stathopoulou, Sotiria; Mauro, Daniele; Goldmann, Katriona; Pyne, Debasish; Rajakariar, Ravindra; Gordon, Patrick; Schafer, Peter; Bombardieri, Michele; Pitzalis, Costantino; Lewis, Myles J Journal: Lupus science & medicine Issue: Volume 8:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. First‐in‐Human, Single‐ and Multiple‐Ascending‐Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator. Issue 5 (23rd September 2020) Authors: Ye, Ying; Gaudy, Allison; Schafer, Peter; Thomas, Michael; Weiss, Daniel; Chen, Nianhang; Liu, Liangang; Xue, Yongjun; Carayannopoulos, Leon; Palmisano, Maria Journal: Clinical pharmacology in drug development Issue: Volume 10:Issue 5(2021) Page Start: 471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis. (February 2019) Authors: Kragstrup, Tue W.; Adams, Mary; Lomholt, Søren; Nielsen, Morten A.; Heftdal, Line D.; Schafer, Peter; Deleuran, Bent Journal: Therapeutic advances in musculoskeletal disease Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P-257 Apremilast Prevents Intestinal Inflammation in Colitis Models via Influencing Epithelial Barrier. (February 2017) Authors: Weigmann, Benno; Popp, Vanessa; Neurath, Markus; Horan, Gerald; Schafer, Peter Journal: Inflammatory bowel diseases Issue: Volume 23(2017)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial. Issue 1 (10th September 2020) Authors: Imafuku, Shinichi; Nemoto, Osamu; Okubo, Yukari; Komine, Mayumi; Schafer, Peter; Petric, Rosemary; Ohtsuki, Mamitaro Journal: Journal of dermatology Issue: Volume 48:Issue 1(2021) Page Start: 80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗